Now playing
01:49
Why this pot investor compares cannabis today to the end of Prohibition
Now playing
02:13
ECB president on women leaders: 'Of course we can do the job'
Now playing
01:36
Michael Bolton wants you to break up with Robinhood
Now playing
01:57
Fed chief downplays inflation concerns
Now playing
04:34
See what has happened to Trump's DC hotel after his loss
Now playing
01:41
Meet the 29-year-old cancer survivor set to make history in space
WASHINGTON, DC - JANUARY 15: MyPillow CEO Mike Lindell waits outside the West Wing of the White House before entering on January 15, 2021 in Washington, DC. (Photo by Drew Angerer/Getty Images)
PHOTO: Drew Angerer/Getty Images
WASHINGTON, DC - JANUARY 15: MyPillow CEO Mike Lindell waits outside the West Wing of the White House before entering on January 15, 2021 in Washington, DC. (Photo by Drew Angerer/Getty Images)
Now playing
00:39
MyPillow and its CEO Mike Lindell sued by Dominion
Bill Gates AC intv 022021
PHOTO: CNN
Bill Gates AC intv 022021
Now playing
02:32
Will Bill Gates go back to shaking hands? Hear his thoughts
02 Bill Gates AC intv 02202021
PHOTO: CNN
02 Bill Gates AC intv 02202021
Now playing
02:13
Bill Gates optimistic about climate policy under Biden WH
Now playing
05:37
Texas mayor: We were not prepared
Now playing
03:05
Watch lawmakers grill Robinhood's CEO
PHOTO: CNN
Now playing
04:47
ERCOT CEO explains how Texas power failure happened
NEW YORK, NEW YORK - OCTOBER 15: A person walks by a closed New York City business on October 15, 2020 in New York City. As American workers continue to struggle in an economy brought down by COVID-19, new jobless claims rose to 898,000 last week. It was the highest number since August 22 and represented a gain of 53,000 from the previous week
PHOTO: Spencer Platt/Getty Images
NEW YORK, NEW YORK - OCTOBER 15: A person walks by a closed New York City business on October 15, 2020 in New York City. As American workers continue to struggle in an economy brought down by COVID-19, new jobless claims rose to 898,000 last week. It was the highest number since August 22 and represented a gain of 53,000 from the previous week's upwardly revised total of 845,000. (Photo by Spencer Platt/Getty Images)
Now playing
01:11
Weekly initial jobless claims jump to 861,000
Now playing
02:42
A challenging year for women: Millions are out of work
MELBOURNE, AUSTRALIA - FEBRUARY 18: In this photo illustration a message is seen on Facebook mobile, on February 18, 2021 in Melbourne, Australia. Facebook has banned publishers and users in Australia from posting and sharing news content as the Australian government prepares to pass laws that will require social media companies to pay news publishers for sharing or using content on their platforms. (Photo by Robert Cianflone/Getty Images)
PHOTO: Robert Cianflone/Getty Images AsiaPac/Getty Images
MELBOURNE, AUSTRALIA - FEBRUARY 18: In this photo illustration a message is seen on Facebook mobile, on February 18, 2021 in Melbourne, Australia. Facebook has banned publishers and users in Australia from posting and sharing news content as the Australian government prepares to pass laws that will require social media companies to pay news publishers for sharing or using content on their platforms. (Photo by Robert Cianflone/Getty Images)
Now playing
03:05
Facebook blocks news sharing in Australia in response to government proposal
PHOTO: Anadolu Agency via Getty Images
Now playing
00:58
Watch Trump's Atlantic City casino implode
(CNN Business) —  

For more than 50 years, if a scientist wanted to conduct a clinical trial using cannabis and needed to obtain the drug, the University of Mississippi has been the only game in town.

The university, since 1968, consistently secured US government contracts to serve as the country’s sole supplier of research-grade cannabis. But that partnership has come under fire in recent years because the product the University of Mississippi grows is considered, as one lawsuit put it, “sub-par.”

On Monday, Ole Miss’ reign came a step closer to coming to an end.

The Drug Enforcement Administration on Monday said it’s now moving forward on a 2016 policy change to allow more entities to grow cannabis for federally approved research. Industry advocates claim such a move would be a boon to not only science but also national legalization efforts — if, that is, the DEA is really going to follow through on what it’s saying.

“The main thing that it will likely do is precipitate broader changes in federal policy in marijuana, which will have immense knock-on effects for the industry,” said David Abernathy, vice president of government affairs at the Arcview Group — a firm that courts investment and conducts market research in the cannabis industry.

However, a leading drug expert and a prominent cannabis researcher both caution that any such expectations should be tempered and that the potential benefits and risks of cannabis use will likely continue to be woefully under-researched.

“I don’t think this should be cause for celebration within the industry at all,” said John Hudak, a senior fellow at the Brookings Institution.

The DEA has had three years to secure inventory and to evaluate security measures and prospective applicants for a proposal that came from the previous administration, Hudak said. In 2017, the efforts were shelved by Attorney General Jeff Sessions, the Washington Post reported at the time.

“I think what this is going to do is buy the DEA quite a bit more time to drag its feet,” Hudak said. “There’s no timeline on this for them to put out their own security guidelines.”

Cannabis growing room of MedPharm Research warehouse. December 7, 2018. MedPharm Holdings, a cannabis research and cultivation company, is one of 33 entities that submitted a DEA application to grow research-grade cannabis.
PHOTO: Hyoung Chang/The Denver Post/Getty Images
Cannabis growing room of MedPharm Research warehouse. December 7, 2018. MedPharm Holdings, a cannabis research and cultivation company, is one of 33 entities that submitted a DEA application to grow research-grade cannabis.

The DEA’s announcement comes two days before the agency had to file a court-ordered response about its efforts to expand cultivation of research-grade cannabis. One entity that has previously applied to grow the drug for research, the Scottsdale Research Institute, sued the DEA earlier this year, alleging that “sub-par” government-provided cannabis interfered with efforts in researching PTSD in veterans.

“We’re cautiously optimistic, and this is a positive first step,” said Matt Zorn, an attorney representing Scottsdale Research Institute and lead researcher Dr. Sue Sisley. “But it took Dr. Sisley three years and a lawsuit just to get to this point, so I wouldn’t say the case is closed.”

Scottsdale Research Institute is responsible for just one of 33 cultivation applications submitted to the DEA since August 2016.

“DEA is making progress in the program to register additional marijuana growers for federally authorized research, and will work with other relevant federal agencies to expedite the necessary next steps,” DEA Acting Administrator Uttam Dhillon said in a statement. “We support additional research into marijuana and its components, and we believe registering more growers will result in researchers having access to a wider variety for study.”

But first, the agency said, it will develop new rules and regulations for how cannabis is cultivated for federally approved research. It did not provide any timetable for doing so. The DEA’s statement also clarified that researchers do not need DEA approval for research using hemp, which was removed as a controlled substance late last year, or hemp-derived CBD.

DEA officials directed media inquiries to the Department of Justice, which did not respond to an interview request or questions submitted by CNN Business. Officials at the University of Mississippi were unavailable for comment.

“The current producer has had a government monopoly for research for decades, and meanwhile, there’s been great innovation happening in other countries around the world in respect to cannabis,” said George Hodgin, a former Navy SEAL whose Biopharmaceutical Research Company submitted an application in 2016.

Hodgin’s plans included growing cannabis to research its effects on veterans experiencing chronic pain and post-traumatic stress disorder. Biopharmaceutical Research Company’s Monterey, California, facility — which Hodgin describes as “Fort Knox without the gold” — has sat empty awaiting the federal OK.

“It has been a long and emotional three years, it feels like we’re going to be able to accomplish our dream, finally,” he said.